Amgen’s Amjevita US Sales On The Rise, Oncology Biosimilars Still In Slump

Amgen Reported 36% Annual Global Sales Increase For Adalimumab Biosimilar After US Launch

 
• By Urtė Fultinavičiūtė
  
Red and blue arrows up and down with dollar coins, mixed fortunes
Amjevita entered the US market at the end of January 2023 • Source: Shutterstock

More from Biosimilars

More from Products